Reducing the risk of infection in a 74-year-old man who is to receive prednisone

CMAJ

Volumn 186, Issue 16, 2014, Pages 1239-1240

  Daniel M, Shafran ^a   Paul E, Bunce ^a,b   Gold, Wayne L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HEPATITIS B SURFACE ANTIGEN; PREDNISONE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

BLISTER; BULLOUS PEMPHIGOID; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG USE; FECES ANALYSIS; HEPATITIS B; HUMAN; INFECTION RISK; LATENT TUBERCULOSIS; MEDICAL DECISION MAKING; PATIENT ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; RISK REDUCTION; SCREENING TEST; SHORT SURVEY; SKIN BIOPSY; STRONGYLOIDIASIS; AGED; CASE REPORT; HEPATITIS B, CHRONIC; MALE; PEMPHIGOID, BULLOUS; PNEUMONIA, PNEUMOCYSTIS; RISK FACTOR;

AGED; GLUCOCORTICOIDS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LATENT TUBERCULOSIS; MALE; PEMPHIGOID, BULLOUS; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RISK REDUCTION BEHAVIOR; STRONGYLOIDIASIS;

EID: 84909619330     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.131430     Document Type: Article

References (13)

1. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26.
2. Canadian Thoracic Society. Canadian tuberculosis standards, 7th edition. Can Resp J 2013;20(Suppl A):1-174.
3. Oxlade O, Schwartzmann K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: cost effectiveness analysis. Int J Tuberc Lung Dis 2007;11:16-26.
4. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus reactivation with immunosuppressive therapy in rheumatic diseases: assessment and prevention strategies. Ann Rheum Dis 2006;65:983-9.
5. Hwang J, Fisch M, Zhang H, et al. Reactivation of hepatitis B infection among patients with cancer. Hepatology 2011;54 (Suppl 4):445A.
6. Coffin CS, Fung SK, Ma MM. Management of chronic hepatitis B: Canadian association for the study of the liver consensus guidelines. Can J Gastroenterol 2012;26:917-38.
7. Lok ASF, McMahon BJ. AASLD Practice Guideline update. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
8. Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 2011;29:3270-7.
9. Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008;10: 105-10.
10. Davidson RA, Fletcher RH, Chapman LE. Risk factors for strongyloidiasis: a case-control study. Arch Intern Med 1984;144:321-4.
11. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71:5-13.
12. Green H, Paul M, Vidal L, et al. Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052-9.
13. Canadian immunization guide. Ottawa: Public Health Agency of Canada; 2013. Available: www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php (accessed 2013 Dec. 11).